Canada Markets closed

GSK plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
36.03+0.30 (+0.84%)
At close: 04:00PM EDT
36.10 +0.07 (+0.19%)
After hours: 07:59PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • G
    Gerry
    Let everyone understand by this example. Yahoo Finance controls the news flow. They haven't even posted the story as to why GSK and SNY are down. It has to do with lawsuits coming over Zantac. I don't know why they won't print the story?
  • b
    blue
    Why is it down today?
  • A
    Anonymous
    Just bought GSK today 3k (1k in 3 different accounts). GSK will fight this lawsuit and win. You take drugs... any form of drugs... at your own risk (and I would add vaccines too). I personally don't touch any of it, but need the dividend income to support my aging father.
  • A
    Astrophysics
    Do US ADR holders suffer dividend withholding if we own this stock?
    Please respond.
  • G
    Greg
    Everyone understand that GSK just cut the dividend by 20% ? Shrewd move, by reverse splitting the GSK shares they managed to cut 20% of the outstanding, so while the dividend stays the same, shareholders lost 20% of their shares, and 20% of the dividend they used to receive. Maybe that's why this is tanking ?
  • a
    al
    It’s a buy at these level. The litigation will go on for years, final settlement should be around $10B, with GSK on the hook for around $3B. Most of the money will be paid by insurance and other third parties. It’s priced in even at $40.
  • m
    m
    Insiders should be buying here
  • B
    Brewster
    GSK statement released:
    "Issued: 11 August 2022, London UK

    Statement: Zantac (ranitidine) litigation



    · FDA and EMA have concluded there is no evidence of a causal association between ranitidine therapy and the development of cancer.

    · Substantial scientific evidence supports FDA/EMA conclusion.

    · Plaintiff litigation inconsistent with the scientific consensus, GSK will vigorously defend all claims.







    In response to recent speculative commentary regarding U.S. Zantac litigation, GSK plc (LSE/NYSE: GSK) today issued the following statement regarding Zantac (ranitidine) and N-nitrosodimethylamine (NDMA).



    There have been no material developments to what has been previously disclosed.



    GSK, independent cancer researchers, the U.S. Food & Drug Administration, and the European Medicines Agency, have all undertaken extensive reviews of available data and conducted numerous investigations into this issue since 2019.



    Based on these investigations and experiments, GSK, the FDA, and the EMA have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients.

    · In November 2019, the FDA determined that levels of NDMA in ranitidine products are similar to levels in common foods like grilled and smoked meats, and that it would conduct tests to fully understand if ranitidine forms NDMA in the human body.

    · In September 2020, the EMA's comprehensive review of epidemiological and post marketing data concluded there is "no evidence of a causal association between ranitidine therapy and the development of cancer in patients."

    · In June 2021, the FDA reported that its testing did not support that ranitidine is converted to NDMA in a general, healthy population, and after reviewing the epidemiological studies found that "…no consistent signals emerged across studies, and studies with comparison to active controls found no association between ranitidine and overall or specific cancer risk."

    These conclusions pertain to all forms of cancer, including but not limited to bladder, breast, colorectal, esophageal, kidney, liver, lung, pancreatic, prostate, and stomach. Even epidemiologic experts hired by the Multi-District Litigation (MDL) Plaintiffs' Steering Committee concluded in their expert reports that the "evidence was not sufficient to support an opinion that use of ranitidine can cause breast, prostate, kidney, lung, or colorectal cancer."
  • t
    tuchalski
    Just saw GSK published on the daily alert watchlist at (http://market-engross.club)
  • J
    John
    Overall, the spinoff of Haleon has hurt the price of Glaxo without a corresponding increase in the Haleon shares to offset the difference. I'm thinking they should have left things the way they were.
  • C
    Chari
    Compare GSK and LLY over a 25 year period. 1997: LLY 80 roughly quadrupled. 1997: GSK 70 and today roughly halved. What a difference!
  • M
    Mr. Perfect
    Sanofi
    Zantac ligations?No other reason,
    $Gsk,sanofi,and Pfizer but Pfizer is holding better than the rest!
  • M
    Mike
    Good entry point here.
  • h
    hydrogenH2
    GSK & HLN & SNY loss 14% value because of a "Smoke Meat" really FDA??

    You can get sicker with Wendy's..KFC...MCD...Doritos...Pepsi & Coke...Burger King..Chipolte..Subways..to name a few

    Here is what FDA says...

    The FDA agency has tested numerous ranitidine products on the market over the past few months, and today we’re releasing a summary of the results we have to date. Through our testing so far, we have found levels of NDMA in ranitidine that are similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats.

    Criminals in USA?? lol
  • a
    a
    re Zantac plaintiffs would need to prove firstly they took the drug, then they would have to prove that zantac caused cancer. then they would have to determine liability. too far fetched also given the decades involved its impossible to prove. i think this has been kicked around between the parties for past few years and nothing has materialised hence no action. this is a threat to force a settlement so lawyers can salvage their costs and reputation but GSK have the best legal defence and wont give up a penny
  • m
    m
    I sold some bonds and doubled my position here. I think this is an overraction and a good chance to get yield from a quality phama company.
  • J
    Johnfod
    Hey! Look!! GSK's on sale! Only $39.99/share!!!
  • S
    Simon
    FDA already researched this drug in the past and concluded its safe. Buy the DIP to make MONEY. I did this when WFC got charged with corruption and made money with WFC. I bought FE when the CEO got charged with fraud and i made money. I bought Disney when they had a problem with florida government and I made money. I bought Activision when CEO got charged with knowing about sex crimes at work and I made a ton of money. This is no different.
  • c
    christopher
    Congratulations to anyone who sold before the spin-off, obviously the right move to make.
  • J
    Johnfod
    Looks like another disappointing day in GSK stock-land. When will it EVER go up and reward its long term (and long suffering) shareholders?? Emma, any input from you on the future of this tanking equity??